Categories AlphaGraphs, Earnings, LATEST

Fitbit shines even as it dials down outlook

In a market session that saw Garmin fly high with earnings, the day got better for the wearables market after Fitbit (FIT) went up as high as 1.6% in trading post-market-close on upbeat first-quarter results.

The wearables maker beat the street consensus for loss per share (adjusted). The net loss, however, inflated to $80.9 million from $60.1 million the same quarter last year.

Fitbit's devices sold and active users since 2014In the first quarter, Fitbit sold 2.2 million wearable devices at almost $112 per device — with the average selling price 16% higher than a year ago. This was achieved by a healthy mix of watches and wearables.

Revenue for the quarter fell 17% to $247.9 million with a gross margin of 46%. Out of this topline, 56% of it or $140 million came from the US, down 18% year-over-year. This resulted in the net loss climbing to $0.34 per year from last year’s $0.27 per share. Adjusted loss, however, was only $41 million or $0.17 per share, just marginally wider than last year’s $34.4 million or $0.15 per share.

Fitbit is seeing a shift to more products as the Ionic, Versa and Aria 2, and the accessory Fitbit Flyer — all launched last year — made up 34% of the quarterly revenue.

As the wearables veteran expects “reduced demand by the channel for trackers,” revenue is estimated to slide 19% year-over-year and to be in a range of $275 million to $295 million in the second quarter, generating a loss of $0.27-$0.23 per share.

Fitbit, however, did not change its fiscal year 2018 revenue guidance of $1.5 billion. The trend of increasing selling prices seem to be still on, as the wearables maker expects it to grow. It’s a bright place on the cash front as well, as Fitbit expects free cash flow to slip lower than revenue, seeing a breakeven in the year.

 

Fitbit Q1 2018 Earnings

The east is calling:

Much of Fitbit’s revenue in the second quarter was made outside the US — 44% of it, to put a number to it. In total, international topline slipped 16%. But the offsetting factor was the Asia-Pacific region (APAC), as revenue jumped 33% to $28 million.

Versa has delivered:

Last week, AlphaStreet reported that Fitbit was aiming for a title in the competitive smartwatch space with its ‘Versa,’ which is compatible with both Android and iOS devices. According to the company, the device, along with Aria 2, contributed to more portion of the revenue.

Learning from the mistakes:

The disaster that was Ionic, was even CEO James Park’s concern. Though Ionic carried many features currently present in Versa, it failed to appeal to the consumers. Fitbit quickly learned from it and employed quick but effective changes to the Versa. This is a fresh perspective for the company in course correction, and it looks like the healthy choice has indeed paid off.

Welcome, Google API:

Fitbit this week announced the adopting of Google Cloud Healthcare API into its fitness tracking devices. While this is a technological leap for the company, it will also doctors to monitor persons wearing Fitbit devices in real time. Looking at how this is going, we could see a revenue jump (if the product doesn’t end up like the Ionic disaster, that is,) in the coming quarters.

As formidable players such as Garmin (GRMN) enter the market with all guns blazing, veterans such as Fitbit has to beat both Apple’s brand and the new fast-rising kids. So far, the company has managed to pull its socks up and deliver. It looks like Fitbit is quite a strong player with limited slips, and could be the unwavering stock tree in this technological segment that sees too many spikes and troughs. The consecutive quarter might decide its fate, however, as the wearables market is looking at a race to determine a new hierarchy.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top